Saniona (SANION.ST) Stock Analysis & AI Equity Report
Saniona (SANION.ST) overview
Saniona (SANION.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Saniona reported revenue of SEK 434m and operating profit of SEK 275m; the year-end share price was 21.20 SEK and market capitalisation was SEK 2,732m. Saniona is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Saniona's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-05-21. Data will be refreshed during report generation.
About Saniona
Saniona AB is a clinical-stage biopharmaceutical company focused on discovering and developing ion channel-based medicines for neurological, psychiatric and other diseases with unmet medical need. Its work centers on an internal pipeline of drug candidates, supported by proprietary ion channel research, with additional programs advanced through partnerships and collaborations with pharmaceutical companies.
Generate the Saniona report
Saniona is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Saniona and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.